Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05446298
Title ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)
Acronym PRESERVE-004
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors OncoC4, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.